Interim Report Q3 – July – September, 2022 Redsense Medical AB (publ)
Focus ahead as US purchasing patterns burden Q3 July – September 2022 · Net sales amounted to kSEK 1,023 (3,566), a decrease of 71.3 percent. · Operating loss, EBIT amounted to kSEK 5,857 (2,852). · Result after tax amounted to kSEK -2,372 (-2,547). · Earnings per share was SEK -0.23 (-0.18) before and after dilution. January – September 2022 · Net sales amounted to kSEK 6,077 (6,008), an increase of 1 percent. · Operating loss, EBIT amounted to kSEK 10,506 (9,218). · Result after tax amounted to kSEK -6,205 (-6,937). · Earnings per share was SEK -0.50 (-0.